Senior Overviews

Lindenmann, Jean

doi:10.1111/j.1365-3083.1984.tb00931.x

Cited by 58 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The discovery of antibodies around 1890 has been variously attributed to Paul Ehrlich, Emil von Behring and Kitasato Shibasaburo and the small proteins have since become wellestablished forms of treatment in a wide spectrum of diseases, including cancer (35,36). They act in a several ways, for example by preventing an antigen from attaching to its receptor on the cell's surface or by marking an antigen to be destructed (21).…”

Section: Antibody-based Therapiesmentioning

confidence: 99%

The Intriguing History of Cancer Immunotherapy

2019

View full text Add to dashboard Cite

Immunotherapy is often perceived as a relatively recent advance. In reality, however, one should be looking for the beginnings of cancer immunotherapy under different names as far as in the Antiquity. The first scientific attempts to modulate patients' immune systems to cure cancer can be attributed to two German physicians, Fehleisen and Busch, who independently noticed significant tumor regression after erysipelas infection. The next significant advances came from William Bradley Coley who is known today as the Father of Immunotherapy. It was Coley who first attempted to harness the immune system for treating bone cancer in 1891. His achievements were largely unnoticed for over fifty years, and several seminal discoveries in the field of Immunology, such as the existence of T cells and their crucial role in immunity in 1967, stepped up the research toward cancer immunotherapy known today. The following paper tracks cancer immunotherapy from its known beginnings up until recent events, including the 2018 Nobel Prize award to James Allison and Tasuku Honjo for their meticulous work on checkpoint molecules as potential therapeutic targets. That work has led to the successful development of new checkpoint inhibitors, CAR T-cells and oncolytic viruses and the pace of such advances brings the highest hope for the future of cancer treatment.

show abstract

Section: Antibody-based Therapiesmentioning

confidence: 99%

The Intriguing History of Cancer Immunotherapy

2019

View full text Add to dashboard Cite

show abstract

“…According to the 'immune network hypothesis' epitopes, the part of the antigens binding antibodies, are transformed in Id-determinants expressed on antibodies [87]. So an antibody takes at the same time the role of an antigen.…”

Section: Results Of Clinical Trials On Immunotherapy For Recurrent Ovmentioning

confidence: 99%

Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

Bronte

Cicero

Sortino

et al. 2013

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Introduction: Treatment of ovarian cancer has been long standardized with the inclusion of surgery and chemotherapy based on platinum and taxanes,\ud this strategy reaching high remission rates. However, when this treatment\ud fails, further options are available with little benefit. Since ovarian cancer\ud has specific immunologic features, actually immunotherapy is under evalua- 15\ud tion to overcome treatment failure in patients experiencing recurrence.\ud Areas covered: Immunogenicity of ovarian cancer and its relationship with\ud clinical outcomes is briefly reviewed. The kinds of immunotherapeutic strategies\ud are summarized. The clinical trials investigating immunotherapy in\ud recurrent ovarian cancer patients are reported. 20\ud Expert opinion: The results of these clinical trials about immunotherapy are\ud interesting, but little clinical benefit has been achieved until now. For this\ud reason, we could conclude that immunotherapy is quite different from other\ud treatment options and it could change the global approach for recurrent\ud ovarian cancer treatment. However, to date only fragmentary findings are 25\ud available to define the real role of immunotherapy in this setting

show abstract

“…The idiotype network hypothesis of Lindenmann [5] and Jerne [6] provides an elegant approach to mimicking the structure of an antigen epitope by an idiotypic determinant on the surface of an antibody. Anti-idiotypic antibodies with surrogate images of carbohydrate antigens that can elicit immunological responses against carbohydrates have been described; e.g., to capsular polysaccharides of N. meningitidis serogroup C [7] and to human tumour cells [8].…”

Section: Mimotope Vaccinesmentioning

confidence: 99%

Mimotope vaccines

Editors¹

2001

Journal of Medical Microbiology

View full text Add to dashboard Cite

Senior Overviews

Cited by 58 publications

References 11 publications

The Intriguing History of Cancer Immunotherapy

The Intriguing History of Cancer Immunotherapy

Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?

Mimotope vaccines

Contact Info

Product

Resources

About